Oppenheimer analyst, Jay Olson, reiterated his Outperform rating on shares of TherapeuticsMD (NASDAQ: TXMD) and believes the company could be ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE